BusinessUltragenyx Stock Rises 9% Despite Trial Setback
Ultragenyx shares rose about 9% this week, trading near $16 after recovering from a low of $12.73 earlier this month. Investors appear optimistic despite a recent trial failure, focusing on upcoming gene therapy launches and trial results.
Asianet Newsable·1d ago

